| Created at | Source | Raw Value | Validated value |
|---|---|---|---|
| April 1, 2022, 3:30 p.m. | usa |
Phase 1: Characterize the effect of IBIO123 compared to placebo on safety and tolerability;Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance |
Phase 1: Characterize the effect of IBIO123 compared to placebo on safety and tolerability;Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance |